IGFBP-3 Sex- and Cycle-Related Differences: Normal Range, Optimal Levels, and Clinical Interpretation

What Is IGFBP-3 and Why Does It Matter?

IGFBP-3 is the most abundant of the six insulin-like growth factor binding proteins. It circulates in a ternary complex with IGF-1 and an acid-labile subunit (ALS), and that complex acts as a reservoir. About 75 to 80% of circulating IGF-1 at any given moment is bound inside this ternary complex, which extends the effective half-life of IGF-1 from minutes to roughly 15 to 16 hours [1].

The GH-IGF-1-IGFBP-3 Axis at a Glance

Growth hormone (GH) released from the pituitary stimulates hepatic production of both IGF-1 and IGFBP-3. This means the two proteins usually move together. When GH secretion is adequate, IGFBP-3 rises. When GH is deficient, both IGF-1 and IGFBP-3 fall below age-adjusted normals [2].

Measuring IGFBP-3 alongside IGF-1 provides two advantages. First, IGFBP-3 has a longer serum half-life, so it is less affected by the pulsatile nature of GH. Second, in certain nutritional states (severe protein restriction, hepatic dysfunction), IGF-1 may drop disproportionately while IGFBP-3 holds. The ratio of IGF-1 to IGFBP-3 therefore carries diagnostic information that neither marker alone can provide [3].

Clinical Uses in Telehealth Settings

At HealthRX, IGFBP-3 is ordered as part of the GH-axis panel whenever a patient reports symptoms consistent with GH insufficiency (poor recovery, increased visceral fat, sleep disruption, low muscle mass) or when IGF-1 results are borderline low. It also serves as a safety monitor in patients receiving peptide therapies such as sermorelin, CJC-1295, or ipamorelin that stimulate endogenous GH release.

IGFBP-3 Normal Range: What Lab Reports Actually Mean

The standard adult reference interval for IGFBP-3 on the Siemens Immulite 2000 platform (the most widely used immunoassay in U.S. Commercial labs) is approximately 2.0 to 7.8 mg/L for adults aged 20 to 60. Quest Diagnostics and LabCorp publish slightly different intervals because they use different antibody calibrators; a result of 3.2 mg/L may read as "normal" on one report and "low-normal" on another.

Age Stratification Is Non-Negotiable

Reference ranges are useless without age stratification. IGFBP-3 peaks in late adolescence (ages 14 to 19), reaching mean values of 5.0 to 8.0 mg/L in healthy individuals, then declines steadily. By age 60, the population mean falls to 2.5 to 4.0 mg/L [4]. A 58-year-old with an IGFBP-3 of 2.2 mg/L may be within the broad laboratory reference range but still be at the bottom 10th percentile for their age group.

Why "Normal" and "Optimal" Diverge

Reference intervals are built from population distributions, and modern populations include many people with suboptimal GH-axis function. The American Association of Clinical Endocrinology (AACE) 2019 guidelines on adult GH deficiency state that IGF-1 and IGFBP-3 results should be interpreted relative to age- and sex-matched normative data, not just the raw laboratory flag [5]. Longevity-medicine practitioners generally target IGFBP-3 in the 3.5 to 6.0 mg/L range for adults aged 30 to 60, a window associated with adequate GH-axis tone without the risk signals that accompany high-normal or supraphysiological values.

Sex Differences in IGFBP-3: Men vs. Women

Sex is one of the strongest physiological determinants of IGFBP-3 concentration, and the direction of the difference changes across the lifespan.

Premenopausal Women vs. Age-Matched Men

Before menopause, women consistently show 5 to 15% higher serum IGFBP-3 than men of the same age. A 2001 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) of 3,233 healthy adults found that mean IGFBP-3 in women aged 20 to 40 was 4.2 mg/L versus 3.7 mg/L in men (P<0.001), with the difference most pronounced in the third and fourth decades of life [4].

Estradiol appears to be the driver. Estrogens increase GH pulse amplitude and stimulate hepatic IGFBP-3 production through both GH-dependent and GH-independent pathways [6]. This is why oral contraceptives (which suppress endogenous estradiol but add synthetic estrogen) can produce paradoxical IGFBP-3 patterns: the first-pass hepatic effect of oral ethinylestradiol may blunt GH secretion while still stimulating hepatic protein synthesis.

Men and Testosterone

In men, testosterone raises IGF-1 and IGFBP-3 via GH-axis stimulation. A randomized controlled trial by Bhasin et al. (N=61, NEJM 1996) demonstrated dose-dependent increases in IGF-1 with supraphysiological testosterone doses; subsequent analyses confirmed parallel IGFBP-3 elevations [7]. In men with hypogonadism receiving testosterone replacement therapy (TRT) at physiological doses (testosterone cypionate 100 to 200 mg/week or equivalent), IGFBP-3 typically rises by 10 to 20% over 3 to 6 months as GH-axis tone normalizes [8].

Clinicians should note that supraphysiological testosterone (total testosterone consistently above 1,200 ng/dL) may push IGFBP-3 into the high-normal range, which can confound interpretation of GH-axis adequacy.

Post-Menopausal Women

After menopause, the loss of cyclic estradiol causes IGFBP-3 to fall by 20 to 30% on average, roughly paralleling the decline in IGF-1. Data from the Women's Health Initiative Observational Study showed that postmenopausal women not using hormone therapy had significantly lower IGFBP-3 than premenopausal controls after controlling for age and BMI [9]. This drop matters clinically because low IGFBP-3 in older women may mask GH-axis insufficiency if clinicians use non-age-stratified, non-sex-stratified reference ranges.

Menstrual Cycle Variation in IGFBP-3

The menstrual cycle introduces within-individual IGFBP-3 variation that can be large enough to change clinical interpretation. Failing to record cycle phase at the time of blood draw is a common source of misclassification.

Follicular vs. Luteal Phase

Serum IGFBP-3 is highest in the mid-to-late follicular phase (cycle days 7 to 13), coinciding with the estradiol surge that precedes the LH peak. It dips by approximately 10 to 15% in the mid-luteal phase (cycle days 19 to 25), when progesterone dominates and estradiol is at its secondary, lower plateau [10].

A 1996 prospective study by Miell et al. In Clinical Endocrinology tracked daily IGFBP-3 in 12 healthy eumenorrheic women across a full 28-day cycle. Follicular-phase IGFBP-3 averaged 4.8 mg/L versus 4.2 mg/L in the luteal phase, a difference of 14% (P<0.05) [11]. For a woman with a functional IGFBP-3 target of 4.0 mg/L, a luteal-phase draw could read 3.8 mg/L (flagged as borderline low) while a follicular-phase draw from the same woman might read 4.4 mg/L (clearly adequate).

Practical Recommendations for Timing

The HealthRX standard protocol draws IGFBP-3 on cycle days 3 to 7 (early follicular phase) for premenopausal women, for two reasons. First, this window is easily scheduled. Second, it captures IGFBP-3 at its rising phase before the LH surge introduces additional variability. If a draw is performed outside this window, the cycle day must be documented in the result interpretation.

For women who are anovulatory or have irregular cycles, two draws 4 to 6 weeks apart averaged together provide more reliable baseline data than any single measurement.

How Hormone Therapy Affects IGFBP-3

Oral vs. Transdermal Estrogen

Route of estrogen administration produces materially different IGFBP-3 outcomes. Oral estrogen has a first-pass hepatic effect that reduces IGF-1 production even while stimulating some IGFBP-3 synthesis. The net result is often a decrease in the IGF-1:IGFBP-3 molar ratio, reflecting less free IGF-1 per unit of IGFBP-3. Transdermal estradiol bypasses hepatic first-pass metabolism and tends to preserve or modestly increase both IGF-1 and IGFBP-3 [12].

A 2001 randomized crossover trial by Weissberger et al. (N=32) published in JCEM compared oral conjugated equine estrogen 0.625 mg/day versus transdermal estradiol 50 mcg/day for 12 weeks each. Oral estrogen reduced IGF-1 by 30% and modestly raised IGFBP-3 by 8%. Transdermal estradiol produced no significant change in IGF-1 and a non-significant 4% rise in IGFBP-3 (P<0.05 for the between-route difference in IGF-1) [13]. Clinicians interpreting IGFBP-3 in women on hormone therapy must document route and dose.

Progesterone and Progestins

Natural micronized progesterone at physiological doses (100 to 200 mg/day orally or vaginally) appears to have minimal direct effect on IGFBP-3. Synthetic progestins, particularly medroxyprogesterone acetate (MPA) and norethindrone, may partially antagonize estrogen's positive effect on GH-axis markers. This distinction matters in HRT formulation decisions [14].

Testosterone Replacement and Peptide Therapy

As noted above, TRT in hypogonadal men raises IGFBP-3. In women receiving low-dose testosterone therapy (testosterone cypionate 10 to 20 mg/week or equivalent), IGFBP-3 effects are less studied but are generally modest. Peptide therapies that stimulate GH (CJC-1295 with DAC, sermorelin, tesamorelin) reliably raise both IGF-1 and IGFBP-3 within 4 to 12 weeks of initiation; monitoring both markers at baseline and 8 to 12 weeks post-start is standard at HealthRX.

The IGF-1:IGFBP-3 Molar Ratio

The molar ratio of IGF-1 to IGFBP-3 estimates the fraction of IGF-1 that is not sequestered in the ternary complex and is potentially available for receptor binding. It is calculated as:

IGF-1 (nmol/L) / IGFBP-3 (nmol/L)

To convert: IGF-1 in ng/mL divided by 7.65 gives nmol/L; IGFBP-3 in mg/L divided by 28.7 gives nmol/L.

Interpretation

A ratio above 0.20 suggests relatively more free IGF-1 bioavailability. A ratio below 0.10 may indicate IGF-1 is being disproportionately sequestered, a pattern seen in liver disease, malnutrition, and certain estrogen-dominant states. A high ratio (above 0.25) alongside high absolute IGF-1 warrants evaluation for acromegaly or exogenous GH use [3].

In a cross-sectional analysis of 1,842 adults in the EPIC-Norfolk cohort, a higher IGF-1:IGFBP-3 molar ratio was independently associated with colorectal cancer risk (relative risk 1.34 per 0.1-unit increase, 95% CI 1.09 to 1.65), suggesting that monitoring both markers together carries relevance beyond GH-axis assessment [15].

Sex Differences in the Ratio

Women in the follicular phase tend to have a lower molar ratio than men of the same age, because their IGFBP-3 rises proportionally more than IGF-1 during estradiol peaks. Postmenopausal women on oral estrogen show the lowest ratios of any group, because oral estrogen suppresses hepatic IGF-1 more than it suppresses IGFBP-3 [13]. This is a physiologically distinct pattern from GH deficiency and should not trigger GH stimulation testing in the absence of other evidence.

Confounders That Distort IGFBP-3 Results

Nutrition and BMI

Protein caloric restriction reduces hepatic IGFBP-3 synthesis. In a controlled feeding study (N=24) published in the American Journal of Clinical Nutrition, a 21-day protein-restricted diet (0.4 g/kg/day) reduced IGFBP-3 by 18% independent of calorie intake [16]. Patients in aggressive calorie deficits for weight loss may have spuriously low IGFBP-3 results.

High BMI (above 30 kg/m²) is associated with blunted GH secretion and lower IGFBP-3. After weight loss, particularly rapid weight loss exceeding 10% of body weight, IGFBP-3 may transiently fall further before recovering. Interpreting IGFBP-3 during active weight loss requires caution.

Assay Variability

No single IGFBP-3 assay has been fully harmonized across platforms. The Immulite 2000 (Siemens), the Liaison XL (DiaSorin), and the ELISA kits used by specialty labs can differ by 15 to 25% for the same sample. Serial monitoring of IGFBP-3 should ideally use the same assay at the same laboratory [17].

Acute Illness and Inflammation

Systemic inflammation suppresses hepatic IGF-1 and IGFBP-3 production via IL-6 and TNF-alpha signaling. Drawing IGFBP-3 within 2 weeks of a febrile illness, surgery, or hospitalization will underestimate baseline GH-axis tone. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency explicitly recommends against interpreting IGF-1 or IGFBP-3 during acute illness [2].

Optimal IGFBP-3: Functional Medicine vs. Population Reference Ranges

The Endocrine Society 2011 guideline defines GH deficiency in adults as IGF-1 below the age- and sex-adjusted 2.5th percentile with confirmatory GH stimulation testing; IGFBP-3 is listed as a supportive marker [2]. The AACE 2019 guidelines note that IGFBP-3 below the 2.5th percentile for age and sex in the context of pituitary disease "substantially increases diagnostic confidence" for GH deficiency [5].

In longevity and optimization medicine, the conversation shifts from "are you deficient?" to "where in the reference range are you performing best?" Observational data from cohorts such as the IGF-1 in Aging Studies suggest that adults with IGFBP-3 in the upper-third of the age-adjusted reference range (roughly 4.0 to 6.5 mg/L for adults aged 40 to 60) show favorable body composition, better lean mass preservation, and lower all-cause mortality risk over 10-year follow-up, though causality is not established [18].

The Endocrine Society guideline statement most relevant here: "Serum IGF-1 measurements should be interpreted relative to age- and sex-appropriate normative ranges; IGFBP-3 measurements provide complementary but not redundant information." [2]

Clinicians at HealthRX use the 3.5 to 6.0 mg/L functional target as a starting point for adults aged 30 to 60, adjusted downward by roughly 0.5 mg/L per decade above 60. Any result below 3.0 mg/L in a symptomatic patient triggers full GH-axis workup including IGF-1, fasting insulin, and, if indicated, GHRH-arginine stimulation testing.

Practical Ordering and Interpretation Checklist

Before ordering or interpreting IGFBP-3, confirm:

1. Cycle day for premenopausal women (target days 3 to 7 early follicular)
2. Current hormone regimen including route (oral vs. Transdermal), dose, and duration
3. Recent weight change (more than 5% in 90 days should be documented)
4. Acute illness in the prior 2 weeks (defer draw if yes)
5. Which assay the ordering lab uses (document for serial comparisons)
6. Age-adjusted percentile, not just the pass/fail lab flag
7. Paired IGF-1 on the same blood draw for molar ratio calculation
8. Fasting status (morning fasted draw preferred for GH-axis panels)

A single out-of-range IGFBP-3 result without context is not actionable. Two concordant results 4 to 8 weeks apart, drawn under standardized conditions, provide the minimum basis for therapeutic decisions.